NEW YORK (GenomeWeb News) – Cancer diagnostics firm AnalizaDx and informatics company Global Health Management Informatics today announced a licensing agreement to offer AnalizaDx's tests in Africa and the Caribbean.
GHMI will start offering the tests in Nigeria and South Africa. Through a network of hospitals and clinical laboratories with which it collaborates, the Houston-based firm will begin offering AnalizaDx's PSA/SIA, a prostate cancer test, which can differentiate the cancer from other benign conditions using a blood sample.
Other tests planned to be offered include breast, colon, ovarian, and other cancers.
"Effective, low-cost diagnostics and screening tests in cancer are especially important in regions in which wide access to advanced, expensive diagnostics tools and procedures is not readily available or accessible,” Arnon Chait, president of AnalizaDx, said in a statement. "Our technology platform provides lab-based solutions that could bring definitive answers to millions using blood-based analysis of protein biomarker structure."
Financial and other terms of the deal were not disclosed.
"We believe this partnership will result in many saved lives, while making good use of precious healthcare resources in both developed and emerging markets in Africa," Debo Awosika-Olumo, president and CEO of GHMI, said. "With operations in the U.S. and Africa, we plan to enable smooth transfer of technology and diagnostics products in the near future."
AnalizaDx is headquartered in Cleveland. Its technology assesses changes to protein biomarkers in biological fluids.